NeuroOne Medical Technologies Corporation - Common Stock (NMTC)
0.8600
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 4th, 8:45 AM EDT
Detailed Quote
Previous Close
0.8600
Open
-
Bid
0.5000
Ask
0.5300
Day's Range
N/A - N/A
52 Week Range
0.5510 - 1.390
Volume
46,094
Market Cap
10.32M
PE Ratio (TTM)
-3.308
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
116,517
Chart
About NeuroOne Medical Technologies Corporation - Common Stock (NMTC)
Neuroone Medical Technologies Corp is a pioneering medical technology company focused on developing innovative solutions for neurological disorders. The company specializes in creating advanced devices and technologies aimed at improving the diagnosis and treatment of conditions such as epilepsy, Parkinson's disease, and chronic pain. Neuroone's offerings include breakthrough electrode systems that facilitate precise brain interaction, enabling better therapeutic outcomes. Through their commitment to research and development, Neuroone seeks to address critical healthcare needs in the neurology field while enhancing patients' quality of life. Read More
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing.
EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
NMTC stock results show that NeuroOne Medical Tech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
NeuroOne Medical Technologies (NASDAQ: NMTC) is committed to improving surgical care options and outcomes for patients suffering from neurological disorders including epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. The company’s minimally invasive and high-definition/high-precision solutions offer combination diagnostic and therapeutic functions for EEG recording, tissue ablation, as well as potentially for deep brain stimulation. Along with three FDA-cleared product families, Evo(R) Cortical Electrodes, Evo(R) sEEG Electrodes, and the OneRF(R) Ablation System, the company is engaged in R&D for drug delivery and spinal cord stimulation programs and is exploring potential applications of its medical technology using artificial intelligence. For more information, visit the company’s website at www.nmtc1.com .
